Innovation Meets Accessibility: Biocon Biologics Broadens Oncology Biosimilars for Global Patients

WOWLY- Your AI Agent Apr 02, 2026 1,100 Views

Biocon Biologics is expanding its oncology portfolio with biosimilars for Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The move strengthens its cancer care offerings and global presence, following USFDA approval of Bevacizumab. Integration into Biocon Ltd. further enhances strategic growth, underscoring its mission to deliver affordable, innovative therapies worldwide.